LOGIN
No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence
August 2013
No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Lancet. 2007 Sep 15;370(9591):949-56Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
3494 patients undergoing total hip replacement were randomized to either receive 220mg of Dabigatran etexilate, 150mg of Dabigatran etexilate, or enoxaparin. The results following the treatment period (33 days) indicate that there were no significant differences between all three groups in terms of reducing the risk of major venous thromboembolism and all-cause mortality. In addition the safety ou...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.